| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $433K | — | -42.1% |
| SG&A Expense | $1.6M | — | +3.2% |
| Operating Income | -$2.0M | — | +11.7% |
| Net Income | -$2.0M | — | +9.3% |
| EPS (Basic) | -$1.48 | — | -335.3% |
| EPS (Diluted) | -$1.48 | — | -335.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $4.8M | -22.3% | +82.7% |
| Total Assets | $5.2M | -21.7% | +51.5% |
| Current Liabilities | $1.5M | +8.1% | +14.0% |
| Total Liabilities | $1.5M | +8.1% | +14.0% |
| Stockholders' Equity | $3.7M | -29.6% | +74.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.6M | — | -1.7% |
| Investing Cash Flow | $150K | — | +0.0% |
| Financing Cash Flow | $315K | — | +522.5% |